Pharsight

1. Bidil patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6465463	AZURITY	Methods of treating and preventing congestive heart failure with hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate	Sep, 2020 (3 years ago)
US6784177	AZURITY	Methods using hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate	Sep, 2020 (3 years ago)

Drugs and Companies using HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE ingredient

Market Authorisation Date: 23 June, 2005

Treatment: Method of treatment of heart failure

Dosage: TABLET;ORAL

Strength	Dosage	Availability
37.5MG;20MG	TABLET;ORAL	Prescription

BIDIL family patents

2. Edarbi patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5583141	AZURITY	Heterocyclic compounds and their use as angiotensin antagonists	Dec, 2013 (10 years ago)
US7157584	AZURITY	Benzimidazole derivative and use thereof	May, 2025 (1 year, 1 month from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5958961	AZURITY	Pharmaceutical composition for angiotensin II-mediated diseases	Jun, 2014 (9 years ago)
US7572920	AZURITY	Benzimidazole derivative and use as a II receptor antagonist	Jan, 2025 (8 months from now)
US9066936	AZURITY	Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent	Mar, 2028 (3 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Feb 25, 2016

Drugs and Companies using AZILSARTAN KAMEDOXOMIL ingredient

NCE-1 date: 25 February, 2015

Market Authorisation Date: 25 February, 2011

Treatment: Treatment of hypertension

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
40 mg and 80 mg	10 Apr, 2020	1	20 Jul, 2022	26 Mar, 2028	Eligible

Strength	Dosage	Availability
EQ 40MG MEDOXOMIL	TABLET;ORAL	Prescription
EQ 80MG MEDOXOMIL	TABLET;ORAL	Prescription

EDARBI family patents

3. Edarbyclor patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5583141	AZURITY	Heterocyclic compounds and their use as angiotensin antagonists	Dec, 2013 (10 years ago)
US7157584	AZURITY	Benzimidazole derivative and use thereof	May, 2025 (1 year, 1 month from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7572920	AZURITY	Benzimidazole derivative and use as a II receptor antagonist	Jan, 2025 (8 months from now)
US9066936	AZURITY	Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent	Mar, 2028 (3 years from now)
US9169238	AZURITY	Solid pharmaceutical composition	Feb, 2030 (5 years from now)
US9387249	AZURITY	Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone	Jul, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Combination(NC)	Dec 20, 2014
New Chemical Entity Exclusivity(NCE)	Feb 25, 2016

Drugs and Companies using AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE ingredient

NCE-1 date: 25 February, 2015

Market Authorisation Date: 20 December, 2011

Treatment: Treatment of hypertension

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
40 mg/12.5 mg and 40 mg/25 mg	19 Apr, 2022	1		01 Jul, 2031

Strength	Dosage	Availability
EQ 40MG MEDOXOMIL;12.5MG	TABLET;ORAL	Prescription
EQ 40MG MEDOXOMIL;25MG	TABLET;ORAL	Prescription

EDARBYCLOR family patents

4. Epaned patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10772868	AZURITY	Enalapril formulations	Mar, 2036 (11 years from now)
US9808442	AZURITY	Enalapril formulations	Mar, 2036 (11 years from now)
US10154987	AZURITY	Enalapril formulations	Mar, 2036 (11 years from now)
US9669008	AZURITY	Enalapril formulations	Mar, 2036 (11 years from now)
US11040023	AZURITY	Enalapril formulations	Mar, 2036 (11 years from now)
US10786482	AZURITY	Enalapril formulations	Mar, 2036 (11 years from now)
US11141405	AZURITY	Enalapril formulations	Mar, 2036 (11 years from now)
US11173141	AZURITY	Enalapril formulations	Mar, 2036 (11 years from now)
US10039745	AZURITY	Enalapril formulations	Mar, 2036 (11 years from now)

Drugs and Companies using ENALAPRIL MALEATE ingredient

Market Authorisation Date: 20 September, 2016

Treatment: Treatment of hypertension; Treatment of heart failure

Dosage: SOLUTION;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
1 mg/mL	31 Aug, 2018	1	10 Aug, 2021	25 Mar, 2036	Eligible

Strength	Dosage	Availability
1MG/ML	SOLUTION;ORAL	Prescription

EPANED family patents

5. Eprontia patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11633374	AZURITY	Compositions and methods for treating epilepsy, seizures and other conditions	Aug, 2040 (16 years from now)
US11433046	AZURITY	Compositions and methods for treating epilepsy, seizures and other conditions	Aug, 2040 (16 years from now)
US11826343	AZURITY	Compositions and methods for treating epilepsy, seizures and other conditions	Aug, 2040 (16 years from now)

Drugs and Companies using TOPIRAMATE ingredient

Market Authorisation Date: 05 November, 2021

Treatment: Indicated for the preventive treatment of migraine in patients 12 years and older

Dosage: SOLUTION;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
25 mg/mL	06 Oct, 2022	1		21 Aug, 2040

Strength	Dosage	Availability
25MG/ML	SOLUTION;ORAL	Prescription

EPRONTIA family patents

6. Evekeo Odt patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10130580	AZURITY	Taste-masked pharmaceutical compositions	Apr, 2024 (6 hours ago)
US11160772	AZURITY	Oral amphetamine composition	Mar, 2037 (12 years from now)
US10441554	AZURITY	Oral amphetamine composition	Mar, 2037 (12 years from now)

Drugs and Companies using AMPHETAMINE SULFATE ingredient

Market Authorisation Date: 16 April, 2021

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

Strength	Dosage	Availability
5MG	TABLET, ORALLY DISINTEGRATING;ORAL	Prescription
10MG	TABLET, ORALLY DISINTEGRATING;ORAL	Prescription
20MG	TABLET, ORALLY DISINTEGRATING;ORAL	Prescription
15MG	TABLET, ORALLY DISINTEGRATING;ORAL	Prescription
2.5MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET, ORALLY DISINTEGRATING;ORAL	Discontinued

EVEKEO ODT family patents

7. Firvanq Kit patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10959948	AZURITY	Composition and method for vancomycin oral liquid	Mar, 2035 (10 years from now)
US10493028	AZURITY	Composition and method for vancomycin oral liquid	Mar, 2035 (10 years from now)
US11638692	AZURITY	Composition and method for vancomycin oral liquid	Mar, 2035 (10 years from now)
US10959947	AZURITY	Composition and method for vancomycin oral liquid	Mar, 2035 (10 years from now)
US10959949	AZURITY	Composition and method for vancomycin oral liquid	Mar, 2035 (10 years from now)
US10959946	AZURITY	Composition and method for vancomycin oral liquid	Mar, 2035 (10 years from now)
US10688046	AZURITY	Composition and method for vancomycin oral liquid	Mar, 2035 (10 years from now)

Drugs and Companies using VANCOMYCIN HYDROCHLORIDE ingredient

Market Authorisation Date: 26 January, 2018

Treatment: Treatment of c. difficile-associated diarrhea

Dosage: FOR SOLUTION;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
25 mg/mL and 50 mg/mL	18 May, 2020	1	14 Nov, 2022	13 Mar, 2035	Eligible

Strength	Dosage	Availability
EQ 50MG BASE/ML	FOR SOLUTION;ORAL	Prescription
EQ 25MG BASE/ML	FOR SOLUTION;ORAL	Prescription

FIRVANQ KIT family patents

8. Fleqsuvy patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11446246	AZURITY	Suspensions and diluents for metronidazole and baclofen	Sep, 2037 (13 years from now)
US11324696	AZURITY	Suspensions and diluents for metronidazole and baclofen	Sep, 2037 (13 years from now)

Drugs and Companies using BACLOFEN ingredient

Market Authorisation Date: 04 February, 2022

Treatment: Indicated for the treatment of spasticity resulting from multiple sclerosis

Dosage: SUSPENSION;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
25 mg/5 mL	20 May, 2022	1	08 Jun, 2023	29 Sep, 2037	Eligible

Strength	Dosage	Availability
25MG/5ML	SUSPENSION;ORAL	Prescription

FLEQSUVY family patents

9. Horizant patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP02744314A	2008-09-04	Breuer, Markus	Patent maintained as amended

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8048917	AZURITY	Prodrugs of GABA analogs, compositions and uses thereof	Nov, 2022 (1 year, 5 months ago)
US6818787	AZURITY	Prodrugs of GABA analogs, compositions and uses thereof	Apr, 2025 (11 months from now)
US8026279	AZURITY	Crystalline form of γ-aminobutyric acid analog	Nov, 2026 (2 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8686034	AZURITY	Crystalline form of γ-aminobutyric acid analog	Jan, 2025 (9 months from now)
US8114909	AZURITY	Treating or preventing restless legs syndrome using prodrugs of GABA analogs	Apr, 2026 (1 year, 11 months from now)
US8795725	AZURITY	GABA analog prodrug sustained release oral dosage forms	Jun, 2029 (5 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE)	Jun 06, 2019
Orphan Drug Exclusivity(ODE-25)	Jun 06, 2019
New Chemical Entity Exclusivity(NCE)	Apr 06, 2016
New Indication(I-652)	Jun 06, 2015

Drugs and Companies using GABAPENTIN ENACARBIL ingredient

NCE-1 date: 07 April, 2015

Market Authorisation Date: 13 December, 2011

Treatment: Management of postherpetic neuralgia (phn) in adults; Treatment of moderate-to-severe primary restless leg syndrome in adults

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
300 mg and 600 mg	29 Apr, 2019	1		10 Jun, 2029

Strength	Dosage	Availability
300MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
600MG	TABLET, EXTENDED RELEASE;ORAL	Prescription

HORIZANT family patents

10. Katerzia patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11701326	AZURITY	Amlodipine formulations	Oct, 2037 (13 years from now)
US11364230	AZURITY	Amlodipine formulations	Oct, 2037 (13 years from now)
US10959991	AZURITY	Amlodipine formulations	Oct, 2037 (13 years from now)
US11484498	AZURITY	Amlodipine formulations	Oct, 2037 (13 years from now)
US10894039	AZURITY	Amlodipine formulations	Oct, 2037 (13 years from now)
US11471409	AZURITY	Amlodipine formulations	Oct, 2037 (13 years from now)
US10952998	AZURITY	Amlodipine formulations	Oct, 2037 (13 years from now)
US10695329	AZURITY	Amlodipine formulations	Oct, 2037 (13 years from now)
US10799453	AZURITY	Amlodipine formulations	Apr, 2039 (14 years from now)

Drugs and Companies using AMLODIPINE BENZOATE ingredient

Market Authorisation Date: 08 July, 2019

Treatment: Angina; Method of treating hypertension; A method of treating hypertension

Dosage: SUSPENSION;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
1 mg/mL	29 Dec, 2020	1	13 Jun, 2023	11 Apr, 2039	Eligible

Strength	Dosage	Availability
EQ 1MG BASE/ML	SUSPENSION;ORAL	Prescription

KATERZIA family patents

11. Konvomep patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10751333	AZURITY	Compositions and kits for omeprazole suspension	Jul, 2039 (15 years from now)
US11103492	AZURITY	Compositions and kits for omeprazole suspension	Jul, 2039 (15 years from now)
US11633478	AZURITY	Compositions and kits for Omeprazole suspension	Jul, 2039 (15 years from now)
US11771686	AZURITY	Compositions and kits for omeprazole suspension	Mar, 2040 (15 years from now)

Drugs and Companies using OMEPRAZOLE; SODIUM BICARBONATE ingredient

Market Authorisation Date: 30 August, 2022

Treatment: Short term treatment of active benign gastric ulcer

Dosage: FOR SUSPENSION;ORAL

Strength	Dosage	Availability
2MG/ML;84MG/ML	FOR SUSPENSION;ORAL	Prescription

KONVOMEP family patents

12. Nymalize patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7070581	AZURITY	Dispenser for medicaments and method and apparatus for making same	Jun, 2023 (9 months ago)
US8517997	AZURITY	Dispenser for medicaments and method and apparatus for making same	May, 2024 (24 days from now)
US10342787	AZURITY	Non-aqueous liquid nimodipine compositions	Apr, 2038 (13 years from now)
US11806338	AZURITY	Non-aqueous liquid nimodipine compositions	Apr, 2038 (13 years from now)
US11207306	AZURITY	Non-aqueous liquid nimodipine compositions	Apr, 2038 (13 years from now)
US10576070	AZURITY	Non-aqueous liquid nimodipine compositions	Apr, 2038 (13 years from now)
US11759457	AZURITY	Liquid nimodipine compositions	Apr, 2038 (13 years from now)
US11517563	AZURITY	Liquid nimodipine compositions	Apr, 2038 (13 years from now)
US11413277	AZURITY	Non-aqueous liquid nimodipine compositions	Apr, 2038 (13 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-46)	May 10, 2020
Orphan Drug Exclusivity(ODE)	May 10, 2020

Drugs and Companies using NIMODIPINE ingredient

Market Authorisation Date: 10 May, 2013

Treatment: A method for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage (sah) from ruptured intracranial berry a...

Dosage: SOLUTION;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
6 mg/mL	29 Nov, 2021	1		16 Apr, 2038

Strength	Dosage	Availability
6MG/ML	SOLUTION;ORAL	Prescription

NYMALIZE family patents

13. Qbrelis patents expiration

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US9463183	July, 2017	FWD Entered	Silvergate Pharmaceuticals, Inc.	KVK-Tech, Inc.

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11771733	AZURITY	Lisinopril formulations	Nov, 2035 (11 years from now)
US11179434	AZURITY	Lisinopril formulations	Nov, 2035 (11 years from now)
US9814751	AZURITY	Lisinopril formulations	Nov, 2035 (11 years from now)
US10940177	AZURITY	Lisinopril formulations	Nov, 2035 (11 years from now)
US10039800	AZURITY	Lisinopril formulations	Nov, 2035 (11 years from now)
US9616096	AZURITY	Lisinopril formulations	Nov, 2035 (11 years from now)
US10265370	AZURITY	Lisinopril formulations	Nov, 2035 (11 years from now)
US9463183	AZURITY	Lisinopril formulations	Nov, 2035 (11 years from now)
US10406199	AZURITY	Lisinopril formulations	Nov, 2035 (11 years from now)

Drugs and Companies using LISINOPRIL ingredient

Market Authorisation Date: 29 July, 2016

Treatment: Method of treating hypertension; Method of treatment of heart failure; Acute myocardial infarction

Dosage: SOLUTION;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
1 mg/mL	24 Oct, 2019	1		06 Nov, 2035	Extinguished

Strength	Dosage	Availability
1MG/ML	SOLUTION;ORAL	Prescription

QBRELIS family patents

14. Sotylize patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11013703	AZURITY	Sotalol compositions and uses of the same	Apr, 2034 (9 years from now)
US10206895	AZURITY	Sotalol compositions and uses of the same	Apr, 2034 (9 years from now)
US11850222	AZURITY	Sotalol compositions and uses of the same	Nov, 2034 (10 years from now)
US9724297	AZURITY	Sotalol compositions and uses of the same	Aug, 2035 (11 years from now)

Drugs and Companies using SOTALOL HYDROCHLORIDE ingredient

Market Authorisation Date: 22 October, 2014

Treatment: Indicated for the treatment of ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgement of the physician are life-threatening; Sotylize is indicated for the maintenanc...

Dosage: SOLUTION;ORAL

Strength	Dosage	Availability
5MG/ML (5MG/ML)	SOLUTION;ORAL	Prescription

SOTYLIZE family patents

15. Thyquidity patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP11711688A	2016-07-11	Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.	Granted and Under Opposition

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9050307	AZURITY	Method for the preparation of a levothyroxine solution	Aug, 2031 (7 years from now)

Drugs and Companies using LEVOTHYROXINE SODIUM ingredient

Market Authorisation Date: 30 November, 2020

Treatment: NA

Dosage: SOLUTION;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
100 mcg/5 mL	28 Dec, 2022	1		06 Aug, 2031

Strength	Dosage	Availability
100MCG/5ML	SOLUTION;ORAL	Prescription

THYQUIDITY family patents

16. Triptodur Kit patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP12172232A	2019-04-04	Generics [UK] Ltd	Granted and Under Opposition
EP08763237A	2017-09-14	Ferring B.V.	Revoked
EP08763237A	2017-09-13	Generics (UK) Ltd	Revoked

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10166181	AZURITY	Slow release pharmaceutical composition made of microgranules	Jun, 2029 (5 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-149)	Jun 29, 2024
Orphan Drug Exclusivity(ODE)	Jun 29, 2024
New Product(NP)	Jun 29, 2020

Drugs and Companies using TRIPTORELIN PAMOATE ingredient

Market Authorisation Date: 29 June, 2017

Treatment: NA

Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

TRIPTODUR KIT family patents

17. Xatmep patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10610485	AZURITY	Methotrexate composition	Jan, 2033 (8 years from now)
US11116724	AZURITY	Methotrexate composition	Jan, 2033 (8 years from now)
US10231927	AZURITY	Methotrexate composition	Jan, 2033 (8 years from now)
US9855215	AZURITY	Methotrexate composition	Jan, 2033 (8 years from now)
US9259427	AZURITY	Methotrexate composition	Jan, 2033 (8 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-137)	Apr 25, 2024
Orphan Drug Exclusivity(ODE-138)	Apr 25, 2024
Orphan Drug Exclusivity(ODE)	Apr 25, 2024

Drugs and Companies using METHOTREXATE SODIUM ingredient

Market Authorisation Date: 25 April, 2017

Treatment: A method for treating acute lymphoblastic leukemia; Treatment of juvenile rheumatoid arthritis

Dosage: SOLUTION;ORAL

XATMEP family patents

18. Zonisade patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11478456	AZURITY	Oral pharmaceutical composition comprising Zonisamide and process of preparation thereof	Aug, 2038 (14 years from now)
US11529333	AZURITY	Oral pharmaceutical composition comprising zonisamide and process of preparation thereof	Aug, 2038 (14 years from now)

Drugs and Companies using ZONISAMIDE ingredient

Market Authorisation Date: 15 July, 2022

Treatment: A method of treating seizures

Dosage: SUSPENSION;ORAL

Pharsight

Azurity patents expiration

1. Bidil patents expiration

BIDIL family patents

2. Edarbi patents expiration

EDARBI family patents

3. Edarbyclor patents expiration

EDARBYCLOR family patents

4. Epaned patents expiration

EPANED family patents

5. Eprontia patents expiration

EPRONTIA family patents

6. Evekeo Odt patents expiration

EVEKEO ODT family patents

7. Firvanq Kit patents expiration

FIRVANQ KIT family patents

8. Fleqsuvy patents expiration

FLEQSUVY family patents

9. Horizant patents expiration

HORIZANT family patents

10. Katerzia patents expiration

KATERZIA family patents

11. Konvomep patents expiration

KONVOMEP family patents

12. Nymalize patents expiration

NYMALIZE family patents

13. Qbrelis patents expiration

QBRELIS family patents

14. Sotylize patents expiration

SOTYLIZE family patents

15. Thyquidity patents expiration

THYQUIDITY family patents

16. Triptodur Kit patents expiration

TRIPTODUR KIT family patents

17. Xatmep patents expiration

XATMEP family patents

18. Zonisade patents expiration

ZONISADE family patents

Related content